Description
DESCRIPTION:
Dr. Foreman reviews a case scenario of a critically ill patient experiencing
partial-onset seizures and a framework for treatment decision-making.
LEARNING
OBJECTIVES:
- Review a framework for therapeutic decision-making for critically ill patients who experience partial onset seizures, including special patient considerations
- Review the efficacy of BRIVIACT® (brivaracetam) CV in patients with and without prior exposure to levetiracetam
- Examine the rationale for considering BRIVIACT IV for critically ill patients with focal seizures
FACULTY
Brandon Foreman, MD
Associate Professor of Neurology & Rehabilitation Medicine and Neurosurgery
Associate Director for Neurocritical Care Research
University of Cincinnati
Cincinnati, Ohio
BRIVIACT INDICATION
BRIVIACT® (brivaracetam) CV is indicated for the treatment of partial-onset seizures in patients 1 month of age and older.
BRIVIACT IMPORTANT SAFETY INFORMATION
BRIVIACT is associated with important warnings and precautions including suicidal behavior and ideation, somnolence, fatigue, dizziness, disturbance in gait and coordination, psychiatric adverse reactions including nonpsychotic and psychotic symptoms, and hypersensitivity reactions (bronchospasm and angioedema). BRIVIACT is contraindicated in patients with a prior hypersensitivity reaction to brivaracetam or any of the inactive ingredients.
In adult adjunctive therapy placebo-controlled clinical trials, the most common adverse reactions (at least 5% for BRIVIACT and at least 2% more frequently than placebo) were somnolence and sedation, dizziness, fatigue, and nausea and vomiting symptoms. Adverse reactions reported in clinical studies of pediatric patients were generally similar to those in adult patients. Adverse reactions with BRIVIACT injection in adult and pediatric patients were generally similar to those observed with BRIVIACT tablets. Other adverse events that occurred in adult patients who received BRIVIACT injection included dysgeusia, euphoric mood, feeling drunk, and infusion site pain.
BRIVIACT is a Schedule V controlled substance.
Please refer to the full Prescribing Information under the Resources tab and visit www.BRIVIACThcp.com.
Contributors
-
Brandon Foreman, MD
Brandon Foreman, MD
Associate Professor of Neurology & Rehabilitation Medicine and Neurosurgery
Associate Director for Neurocritical Care Research
University of Cincinnati
Cincinnati, Ohio